KPL
Composite scorecard: 45/100 — Quality 75 · Valuation 3
| Share price | ₹2,743.00 |
| P/B ratio | 8.1 |
| ROE | 22.7% |
| Book value | ₹319.66 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹503 Cr | ₹67 Cr | 24.0% |
| 2025 | ₹370 Cr | ₹40 Cr | 22.0% |
| 2024 | ₹307 Cr | ₹24 Cr | 22.0% |
| 2023 | ₹251 Cr | ₹19 Cr | 24.0% |
| 2022 | ₹456 Cr | ₹120 Cr | 38.0% |
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, and various other categories such as general, beta-l